Your browser doesn't support javascript.
CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity.
Long, Yiru; Sun, Jianhua; Song, Tian-Zhang; Liu, Tingting; Tang, Feng; Zhang, Xinxin; Ding, Longfei; Miao, Yunqiu; Zhu, Weiliang; Pan, Xiaoyan; An, Qi; Qin, Mian; Tong, Xiankun; Peng, Xionghua; Yu, Pan; Zhu, Peng; Xu, Jianqing; Zhang, Xiaoyan; Zhang, Yachun; Liu, Datao; Chen, Ben; Chen, Huilin; Zhang, Leike; Xiao, Gengfu; Zuo, Jianping; Tang, Wei; Zhou, Ji; Li, Heng; Xu, Zhijian; Zheng, Hong-Yi; Long, Xin-Yan; Qin, Qiuping; Gan, Yong; Ren, Jin; Huang, Wei; Zheng, Yong-Tang; Jin, Guangyi; Gong, Likun.
  • Long Y; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Sun J; University of Chinese Academy of Sciences, Beijing, China.
  • Song TZ; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Liu T; University of Chinese Academy of Sciences, Beijing, China.
  • Tang F; University of Chinese Academy of Sciences, Beijing, China.
  • Zhang X; Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China.
  • Ding L; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Miao Y; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Zhu W; University of Chinese Academy of Sciences, Beijing, China.
  • Pan X; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • An Q; University of Chinese Academy of Sciences, Beijing, China.
  • Qin M; Shanghai Public Health Clinical Center & Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
  • Tong X; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Peng X; University of Chinese Academy of Sciences, Beijing, China.
  • Yu P; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Zhu P; University of Chinese Academy of Sciences, Beijing, China.
  • Xu J; University of Chinese Academy of Sciences, Beijing, China.
  • Zhang X; State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, China.
  • Zhang Y; Shanghai King-Cell Biotechnology Co., Ltd, Shanghai, China.
  • Liu D; Zhongshan Institute for Drug Discovery, Institutes of Drug Discovery and Development, Chinese Academy of Sciences, Zhongshan, Guangdong, China.
  • Chen B; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Chen H; University of Chinese Academy of Sciences, Beijing, China.
  • Zhang L; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Xiao G; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Zuo J; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Tang W; Shanghai Public Health Clinical Center & Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
  • Zhou J; Shanghai Public Health Clinical Center & Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
  • Li H; Shanghai King-Cell Biotechnology Co., Ltd, Shanghai, China.
  • Xu Z; Mabwell (Shanghai) Bioscience Co., Ltd, Shanghai, China.
  • Zheng HY; Mabwell (Shanghai) Bioscience Co., Ltd, Shanghai, China.
  • Long XY; Mabwell (Shanghai) Bioscience Co., Ltd, Shanghai, China.
  • Qin Q; University of Chinese Academy of Sciences, Beijing, China.
  • Gan Y; State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, China.
  • Ren J; University of Chinese Academy of Sciences, Beijing, China.
  • Huang W; State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, China.
  • Zheng YT; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Jin G; University of Chinese Academy of Sciences, Beijing, China.
  • Gong L; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Cell Discov ; 8(1): 9, 2022 Feb 01.
Article in English | MEDLINE | ID: covidwho-1661959
ABSTRACT
Safe, effective, and economical vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed to achieve adequate herd immunity and end the pandemic. We constructed a novel SARS-CoV-2 vaccine, CoVac501, which is a self-adjuvanting peptide vaccine conjugated with Toll-like receptor 7 (TLR7) agonists. The vaccine contains immunodominant peptides screened from the receptor-binding domain (RBD) and is fully chemically synthesized. It has been formulated in an optimized nanoemulsion formulation and is stable at 40 °C for 1 month. In non-human primates (NHPs), CoVac501 elicited high and persistent titers of protective neutralizing antibodies against multiple RBD mutations, SARS-CoV-2 original strain, and variants (B.1.1.7 and B.1.617.2). Specific peptides booster immunization against the B.1.351 variant has also been shown to be effective in improving protection against B.1.351. Meanwhile, CoVac501 elicited the increase of memory T cells, antigen-specific CD8+ T-cell responses, and Th1-biased CD4+ T-cell immune responses in NHPs. Notably, at an extremely high SARS-CoV-2 challenge dose of 1 × 107 TCID50, CoVac501 provided near-complete protection for the upper and lower respiratory tracts of cynomolgus macaques.

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines / Variants Language: English Journal: Cell Discov Year: 2022 Document Type: Article Affiliation country: S41421-021-00370-2

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines / Variants Language: English Journal: Cell Discov Year: 2022 Document Type: Article Affiliation country: S41421-021-00370-2